Major prevalence of cancer and rising awareness regarding advanced cancer treatments are some of the key factors driving market revenue growth
The global T-cell therapy market size is expected to reach USD 21 Billion in 2028 and register a CAGR of 20.4% over the forecast period, according to the latest report by Reports and Data. Key factors such as increasing geriatric population globally, rising awareness about advanced cancer treatments, and major prevalence of cancers are driving market revenue growth. T-cell therapy is a type of immunotherapy that involves genetic modification of T-cells. This process is used to treat different types of cancers.
There are mainly three main types of T-cell therapies; CAR T-cell therapy, T-cell receptor (TCR)-based, and tumor infiltrating lymphocytes (TIL)-based. CAR T-cell therapy or Chimeric Antigen Receptor T-cell therapy is one of the most effective methods of cancer treatment. CAR T-cell therapy segment accounted for majority revenue share in the global market in 2020. This can be attributed to increasing number of clinical trials for CAR T-cell therapy and increasing investment in research related to CAR T-cell therapy.
North America accounted for second-largest revenue share in the global market in 2020. Major revenue contributors to revenue of the North America market are the United States and Canada, respectively. Factors such as growing number of clinical trials of T-cell therapies being conducted are driving revenue growth of the market in this region.
Key companies profiled in the report include
Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc., Bluebird Bio Inc., Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., Amgen, and Celgene Corporation.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2508
The report is an investigative study that determines market growth and market scope on the basis of market trends, consumer behavior shifts, consumption and production patterns, product portfolio offered by the market, growth rate, drivers and constraints, financial positions, and existing challenges and limitations of the T-Cell Therapy market.
The report discusses in detail the global production capacity, demand and supply ratio, market dynamics, and comprehensive analysis of the competitive landscape. It provides an industry-wide analysis of the market share of each players along with their business portfolio, production and manufacturing capacity, product portfolio, business expansion plans, financial standing, and strategic alliances such as mergers and acquisitions, joint ventures, and collaborations, among others.
Order this Report @ https://www.reportsanddata.com/report-pricing/2508
The regional bifurcation of the market analyzes key market segments such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. The report discusses in detail the market growth, market size, revenue growth, market share, production and consumption, demand and supply, current and emerging trends, and technological developments in each region.
The key geographical regions analyzed in the market report are:
- North America (U.S.A., Canada)
- Europe (U.K., Italy, Germany, France, Rest of EU)
- AsiaPacific (India, Japan, China, South Korea, Australia, Rest of APAC)
- Latin America (Chile, Brazil, Argentina, Rest of Latin America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
T-Cell Therapy Market Segmentation based on Types:
Modality Outlook (Revenue, USD Billion; 2018-2028)
- Research
- Commercialized
Therapy Outlook (Revenue, USD Billion; 2018-2028)
- CAR T-cell therapy
- T-cell receptor (TCR)-based
- Tumor infiltrating lymphocytes (TIL)-based
Indication Outlook (Revenue, USD Billion; 2018-2028)
- Hematologic Malignancies
- Lymphoma
- Myeloma
- Leukemia
- Solid Tumors
- Brain & Central Nervous System
- Liver Cancer
- Melanoma
- Others
Some Key Highlights from the Report:
In January 2021, OrganaBio launched a new cell product, ImmunoPAC-T-CB T cells. These cells are obtained from full-term umbilical cord blood taken from donors that supports allogeneic immune cell-based therapy development.
Research segment accounted for largest revenue share in the global market in 2020. This can be attributed to rising focus on research of T-cell therapy, and increasing investment in cell therapy-based clinical research and development activities.
Request a customization on the report @ https://www.reportsanddata.com/request-customization-form/2508
Thank you for reading our report. For further inquiry or query about customization, kindly get in touch with us to know more. Our team will clear your doubts and ensure the report is customized to meet your requirements.
Browse More Reports:
Electronic Skin Market @ https://www.biospace.com/article/electronic-skin-market-to-reach-usd-20-02-billion-by-2027-says-reports-and-data/
Dual Chamber Prefilled Syringes Market @ https://www.biospace.com/article/dual-chamber-prefilled-syringes-market-to-reach-usd-223-3-million-by-2028-says-reports-and-data/
Nucleic Acid Isolation and Purification Market @ https://www.biospace.com/article/nucleic-acid-isolation-and-purification-market-size-to-reach-usd-6-17-billion-by-2028-says-reports-and-data/
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us:
John W
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
